Treatment for Specific Phobias in Children

This study has been completed.

Sponsor:

Information provided by:

National Institute of Mental Health (NIMH)

ClinicalTrials.gov Identifier:

NCT00051220

First received: January 7, 2003

Last updated: June 12, 2008

Last verified: June 2008

History of Changes

Purpose

This study will compare the effectiveness of three treatments in reducing symptoms of phobia in children and adolescents.

Condition	Intervention	Phase
Phobic Disorders Anxiety Disorders	Behavioral: One-Session Treatment for Specific Phobias	Phase 1 Phase 2

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Treatment
Official Title:	One-Session Treatment for Specific Phobias in Children

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Phobias

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:	240
Study Start Date:	October 2001
Study Completion Date:	September 2006
Primary Completion Date:	September 2006 (Final data collection date for primary outcome measure)

Detailed Description:

Children with specific phobias may experience academic, social, and personal distress, as well as interference in day-to-day activities. One-Session Treatment has been found a rapid and effective treatment for adults with phobic disorders. However, its utility in the treatment of childhood phobia has not been examined.

Participants are randomly assigned to 1 of 3 groups: a one-session treatment group, an education/support group, and a waitlist control group. The one-session treatment group is directly exposed to a phobia object or situation during a 3-hour treatment session. In the education/support group, children are given information about fear and phobias and are taught how to deal with them through workbook activities. Children who participate in the one-session treatment group or the education/support group are assessed 1 week post-treatment and again after 6 months. Participants with improved symptoms have a 1-year follow-up. Participants with phobias that persist at 6 months are encouraged to participate in alternative treatment. Waitlist control participants are assessed pre-treatment and 1 month post-treatment. Those who continue to have phobias at the 1-month assessment are randomly assigned to 1 of the 2 active treatments.

Eligibility

Ages Eligible for Study:	7 Years to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Primary diagnosis of specific phobia disorder

Exclusion Criteria:

Mental retardation
Developmental disabilities
Suicide threat

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051220

Locations

United States, Virginia
VA Polytech. Institute and State University
Blacksburg, Virginia, United States
Sweden
University of Stockholm
Stockholm, Sweden

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

No publications provided

Responsible Party:	Thomas Ollendick, Ph.D., Licensed Clinical Psychologist, Virginia Tech
ClinicalTrials.gov Identifier:	NCT00051220 History of Changes
Other Study ID Numbers:	R01 MH59308, DSIR CT-S
Study First Received:	January 7, 2003
Last Updated:	June 12, 2008
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Anxiety Disorders
Phobic Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 19, 2013

To Top